Diabetes complications

Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials

Diabetes CarePublished Secondary analysis of the CANVAS and CREDENCE randomised controlled trials

Authors' conclusion

The kidneyintelX.dkd score adds prognostic value beyond clinical classification, reflects canagliflozin treatment response, and helps identify individuals most likely to benefit from therapy. These findings support a role for the kidneyintelX.dkd score in personalized risk assessment and monitoring in type 2 diabetes and CKD in prospective studies and clinical practice.

Study context

Population
Participants with T2D and chronic kidney disease (CKD) G1-G3b from the CANVAS and CREDENCE trials
Comparison
kidneyintelX.dkd score vs Kidney Disease Improving Global Outcomes (KDIGO) risk classification; canagliflozin vs placebo
Methodological detailsbiomarker study, banked plasma samples at baseline and year 1
  • Biomarker study
  • Banked plasma samples at baseline and year 1

Primary result

As reported in the abstract

Association of kidneyintelX.dkd with kidney outcomes · baseline and 1 year
  • Mean kidneyintelX.dkd scores increased across higher KDIGO risk categories; individual-level differences revealed improved risk reclassification
  • kidneyintelX.dkd score independently associated with kidney outcomes and more strongly predictive than KDIGO classification
  • Reductions in kidneyintelX.dkd by 1 year associated with lower subsequent risk of kidney outcomes, independent of changes in eGFR or urinary albumin-to-creatinine ratio

Further findings

kidneyintelX.dkd score, canagliflozin vs placebo · 1 year

Canagliflozin significantly lowered kidneyintelX.dkd score vs placebo

Absolute risk reduction with canagliflozin by kidneyintelX.dkd risk

Absolute risk reductions with canagliflozin largest among those at high kidneyintelX.dkd risk

Original publication

Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials. Diabetes Care. Published 11 November 2025. doi:10.2337/dc25-1722

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.